Can Allogeneic Hematopoietic Cell Transplantation Outcome be Improved by Intravenous Apoptotic Cell Infusion?
|Philippe Saas1,3*, Béatrice Gaugler1,3 and Sylvain Perruche1,3|
|1INSERM UMR645, 1 Bd A Fleming, F25020 Besançon cedex, France|
|2Université de Franche-Comté, IFR133, F25020 Besançon cedex, France|
|3EFS Bourgogne Franche-Comté, F25020 Besançon cedex, France|
|Corresponding Author :||Philippe Saas
INSERM UMR645, UFC
EFS Bourgogne Franche-Comté, 1 boulevard A Fleming
F25020 Besançon Cedex, France
Tel: +33 381615615
Fax: +33 381615800
E-mail: [email protected]
|Received October 10, 2011; Accepted November 09, 2011; Published November 11, 2011|
|Citation: Saas P, Gaugler B, Perruche S (2011) Can Allogeneic Hematopoietic Cell Transplantation Outcome be Improved by Intravenous Apoptotic Cell Infusion? J Cell Sci Ther S7:001. doi: 10.4172/2157-7013.S7-001|
|Copyright: © 2011 Saas P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Cell-based therapy approaches have been shown to improve allogeneic hematopoietic cell transplantation (AHCT) outcome by reducing its severe toxic side effects, including graft rejection, acute and chronic graft-versus-host disease (GvHD) or delayed/ impaired immune reconstitution. Here, we discuss the use of intravenous apoptotic leukocyte infusion to improve AHCT outcome. In experimental AHCT models, we demonstrated that intravenous apoptotic leukocyte infusion, simultaneously to allogeneic bone marrow grafts, favors hematopoietic engraftment, prevents allo-immunization and delays acute GvHD onset. Here, we review the different mechanisms and the potential beneficial effects associated with the immunomodulatory properties of apoptotic cells in the AHCT setting.